Trials / Withdrawn
WithdrawnNCT00060554
A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Schering-Plough · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fondaparinux sodium | |
| DRUG | heparin | |
| PROCEDURE | percutaneous coronary intervention (PCI) |
Timeline
- Start date
- 2003-04-01
- First posted
- 2003-05-08
- Last updated
- 2009-11-03
Locations
26 sites across 3 countries: United States, Canada, France
Source: ClinicalTrials.gov record NCT00060554. Inclusion in this directory is not an endorsement.